Publications by authors named "K Van der Eecken"
Article Synopsis
- - There is a need for better tools to help manage oligometastatic castration-sensitive prostate cancer (omCSPC), as highlighted in a retrospective study examining the effectiveness of the ArteraAI Prostate Test.
- - This study involved 222 men and measured outcomes like overall survival (OS) and time until the cancer becomes castration-resistant, finding a high MMAI score linked to worse OS and shorter time to resistance.
- - Additionally, the study indicated that patients with high MMAI scores who received metastasis-directed therapy (MDT) had improved metastasis-free survival compared to those with low scores, pointing to the potential of the MMAI biomarker for guiding treatment decisions.
Article Synopsis
- Oligometastatic castration-sensitive prostate cancer (omCSPC) is an early stage of metastatic disease with varying outcomes among patients, leading to a study on the impact of tumor genomics on disease progression and failure patterns after treatment.
- A multi-institutional analysis of 267 men who underwent tumor sequencing highlighted that the presence of specific genomic mutations, like TP53, could influence modes of progression and overall survival rates.
- The findings suggested that patients with oligoprogression had significantly better three-year overall survival rates (91%) compared to those with polyprogression (71%), indicating the importance of genomic profiling in predicting clinical outcomes.
De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical intervention in 43 de novo metastatic prostate cancers to assess somatic genotypes across 607 synchronous primary and metastatic tissue regions plus circulating tumor DNA. Intra-prostate heterogeneity was pervasive and impacted clinically relevant genes, resulting in discordant genotypes between select primary restricted regions and synchronous metastases.
View Article and Find Full Text PDFPurpose: Despite well-informed work in several malignancies, the phenotypic effects of TP53 mutations in metastatic castration-sensitive prostate cancer (mCSPC) progression and metastasis are not clear. We characterized the structure-function and clinical impact of TP53 mutations in mCSPC.
Patients And Methods: We performed an international retrospective review of men with mCSPC who underwent next-generation sequencing and were stratified according to TP53 mutational status and metastatic burden.
Unlabelled: In prostate cancer, there is an urgent need for objective prognostic biomarkers that identify the metastatic potential of a tumor at an early stage. While recent analyses indicated TP53 mutations as candidate biomarkers, molecular profiling in a clinical setting is complicated by tumor heterogeneity. Deep learning models that predict the spatial presence of TP53 mutations in whole slide images (WSI) offer the potential to mitigate this issue.
View Article and Find Full Text PDF